Minireviews
Copyright ©The Author(s) 2021.
World J Gastroenterol. Aug 28, 2021; 27(32): 5376-5391
Published online Aug 28, 2021. doi: 10.3748/wjg.v27.i32.5376
Figure 1
Figure 1 Histopathological changes of inhibitor-related hepatotoxicity. A: Prominent perivenulitis (black arrow) with endothelialitis (orange arrow) in a case of ipilimumab related hepatotoxicity (hematoxylin and eosin, 400 ×); B: Lymphocytic cholangitis with prominent duct damage secondary to nivolumab (black arrows; hematoxylin and eosin, 400 ×).